Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease

Jul 22, 2021

Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July

Jul 13, 2021

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 9, 2021

Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints

Jun 30, 2021

Processa Pharmaceuticals Enters Into A Licensing Agreement With Ocuphire Pharma, Inc., For The Development Of RX-3117

Jun 17, 2021

Ocuphire Announces Addition to the Russell Microcap® Index

Jun 11, 2021

Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market

Jun 8, 2021

Ocuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to Its Board of Directors

Jun 8, 2021

Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 4, 2021

Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis

May 20, 2021